First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis-Reference-Cited by-同舟云学术

First‐line ibrutinib treatment in patients with chronic lymphocytic leukemia is associated with overall survival rates similar to those of an age‐matched general population: A pooled post hoc analysis

Published:2024-05 Issue:5 Volume:8 Page:
ISSN:2572-9241
Container-title:HemaSphere
language:en
Short-container-title:HemaSphere

Author:

Ghia Paolo¹^ORCID,Owen Carolyn²,Allan John N.³,Barrientos Jacqueline C.⁴,Barr Paul M.⁵,Shi Chunxue⁶,Szoke Anita⁷,Abbazio Christopher⁷,Krigsfeld Gabriel S.⁷,Burger Jan A.⁸

Affiliation:

1. Division of Experimental Oncology Università Vita‐Salute San Raffaele and IRCCS Ospedale San Raffaele Milan Italy

2. Tom Baker Cancer Centre University of Calgary and Alberta Health Services Calgary Alberta Canada

3. Weill Cornell Medicine New York New York USA

4. Columbia University Division of Hematology/Oncology at Mount Sinai Medical Center Miami Florida USA

5. Wilmot Cancer Institute University of Rochester Medical Center Rochester New York USA

6. Biostatistics, Everest Clinical Research Owings Mills Maryland USA

7. AbbVie Inc, North Chicago, Illinois, USA (Pharmacyclics LLC, an AbbVie Company) South San Francisco California USA

8. Department of Leukemia The University of Texas MD Anderson Cancer Center Houston Texas USA

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hem3.74

Reference15 articles.

1. Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia

2. Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia

3. Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial

4. Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of ibrutinib dose adjustment on TTNT in first-line CLL/SLL: a real-world analysis using target trial emulation;Blood Neoplasia;2024-09

2. The new life of ibrutinib therapy in CLL: enhancing personalized approaches;Expert Review of Anticancer Therapy;2024-07-15